Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496938 | 0.78 | NPC1 (0.43) | SMN1; SMN2ALDH1A1LMNAPOLBRXFP1 | |
| SCHEMBL6505104 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1LMNAKDM4EPOLB | |
| SCHEMBL6505175 | 0.76 | AKR1C3 (0.41) | ALDH1A1LMNAKDM4EPOLBMAPT | |
| SCHEMBL6507421 | 0.72 | AKR1C3 (0.38) | ALDH1A1LMNAKDM4EPOLBMAPT | |
| SCHEMBL6773129 | 0.70 | KMT2A (0.43) | ALDH1A1LMNAKDM4EPOLBMAPT | |
| SCHEMBL4903460 | 0.68 | BRD4 (0.50) | SMN1; SMN2ALDH1A1LMNAKDM4EMAPT | |
| SCHEMBL6305765 | 0.68 | MAPT (0.48) | SMN1; SMN2ALDH1A1LMNAKDM4EMAPT | |
| SCHEMBL11801783 | 0.65 | GAA (0.56) | SMN1; SMN2ALDH1A1LMNAKDM4EMAPK1 | |
| SCHEMBL38660129 | 0.64 | PDE4B (0.51) | SMN1; SMN2ALDH1A1MAPTRAB9APDE4A | |
| SCHEMBL7399792 | 0.64 | AXL (0.45) | SMN1; SMN2ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861529-B2 | Cycloalkylpyrrole-3-carboxylic acid amide derivatives and heterocycloalkylpyrrole-3-carboxylic acid amide derivatives that bind with high affinity to the benzodiazepine site of GABA-A (gamma-aminobutyric acid) receptors | PFIZER INC (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1404316-A1 | CYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND HETEROCYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AS GABA-A RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030069416-A1 | Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives | PFIZER INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2003004018-A1 | CYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND HETEROCYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AS GABA-A RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069416-A1 | Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives | GABARAP, GABRA3, GABRA2 | SMN1; SMN2 2085/4885ALDH1A1 409/4885LMNA 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.